주요 내용으로 건너 뛰기
/ 자료 / 컨퍼런스 / ISPOR Europe 2024

ISPOR Europe 2024

ISPOR Europe 2024

We are excited to be presenting at this conference

Breakout: Are There Any Mutual Learnings on Health Policy Among CEE Countries?

Moderator: Malwina Holownia, MSc, PhD, Certara

Panelist: Gergo Meresz, PhD, MediConcept

Panelist: Oresta Piniazhko, PhD, Ukraine Ministry of Health

Panelist: Eva Turk, PhD, MBA, Slovenia Ministry of Health

Browse Certara Posters and Abstracts by Topic:

Artificial Intelligence (AI)

Can Artificial Intelligence (AI) Accurately Screen Abstracts in Systematic Literature Reviews? ​
Dmitry Gltyaev, Noemi Hummel, Linnea Koller, Lee Stern, Ananth Kadambi, Carl de Moor

Digital Health Technologies

A Comparative Analysis of Requirements for Gaining Market Access of Digital Health Technologies in Germany, Spain, Poland, and Hungary​
Kurt Neeser, Michael Heupel, Malwina Holownia

Gene Therapies

Drivers of Access to Gene Therapies in Poland and Selected Central and Eastern Europe Countries
Elzbieta Soltysiak, Katarzyna Lasota, Gabrielle DeOcampo, Sanja Stanisic, Malwina Holownia

Finding a Way for Patients to Access Gene Therapies​
Katarzyna Lasota, Elzbieta Soltysiak, Gabrielle DeOcampo, Matias Junghahn, Sanja Stanisic, Maximillian Vargas, Roman Casciano

Joint Clinical Assessment (JCA)

National Perspectives on the European Joint Clinical Assessment: Insights from HTA Stakeholders in Four Countries
Elvira Muller, Kurt Neeser, Linnea Koller

Benefit vs. Uncertainties: The Potential Impact of Joint Clinical Assessment (JCA) on Market Access and Reimbursement of Novel Drugs
Kurt Neeser, Elvira Muller

Bridging the Gap: Should Health Policy Practices from Western Europe Influence CEE Countries
Malwina Holownia, Grzegorz Obrzut, Jacek Walczak, Roman Casciano

Real-World Evidence

Leveraging Real-World Evidence to Extend Drug-Drug Interaction Assessment From Drug Development to Clinical Care: A Targeted Review of the Literature ​
Nadia Quignot, Nina Shigesi, Kazue Kikuchi, Sophie Argon, Isabelle Ragueneau-Majilessi

Weight Loss Therapies

Is There an Opportunity for Reimbursement of Anti-Obesity Drugs in Central and Eastern Europe
Katarzyna Lasota, Malwina Holownia, Roman Casciano, Jacek Walczak

Other Topics

Cost-Consequence Analysis of Cabozantinib in Combination With Nivolumab in Treatment of First-Line Advanced Renal Cell Carcinoma in Germany: A Payer Perspective
Dmitry Gltyaev, Emmanuelle Kaltenbach, Mickael Lothgren, Julia Stiefel, Jens Kisro

Impact of Anaemia and Transfusion on Healthcare Resource Utilisation in Patients With Myelofibrosis in France
Alex Slowley (1), Celine Pribil (2), Naima Kerbouche (2), Gaëlle Nachbaur (2), Nadia Quignot (3), Giancarlo Pesce (4), Heng Jiang (5), Cacylde Amouzou (2), JJ Kiladjian (6)

Carbetocin for the prevention of postpartum haemorrhage due to uterine atony following vaginal delivery – a retrospective cost-benefit analysis based on clinical experience from Polish medical centres ​
Adam Bierut, M. Kozlowski, S. Kwiatkowski, Patryk Miernik, P. Oszukowski, Kinga Pacocha, Izabela Pieniazek, A. Pięta-Dolińska, A. Spiczonek, K. Zielińska, J. Zwoliński

Expert EU Health Technology Assessment (HTA) Services

Prepare timely and high quality Joint Clinical Assessment (JCA) deliverables to achieve European market access goals

The European Commission is implementing the Regulation on Health Technology Assessment (HTA) to be applied from 2025 onward. The rules are meant to “facilitate better access to evidence-based healthcare and innovative technologies to patients across Europe.”

To achieve the benefits promised by the new regulation, health technology developers (HTDs) need a flexible and knowledgeable strategic partner that is well versed in the expectations of EU HTA authority and national/regional HTA bodies.

As an industry leader, Certara’s global HTA and market access experts provided guidance and support to clients in the context of programs such as EMA-HTA Parallel Scientific Advice and EUnetHTA Joint Assessments, both of which functioned as pilot programs for the new EU Joint Clinical Assessments (JCA) and Joint Scientific Consultations (JSC) starting in 2025.

Certara can provide strategic support for:

  • Workshops and training on EU HTA regulation (JCA and JSC)
  • PICO scenario planning
  • Data review and evidence synthesis to identify and fill data gaps
  • Comparative effectiveness research (NMA, MAIC, STC, and other complex methods as needed)
  • Complete JCA support including:
  • Guidance and development of submission strategy
  • Project management to ensure critical deadlines are met
  • Writing and compilation of the JCA EU HTA submission dossier
  • Development of complementary national dossiers
  • Participation in HTA/regulatory discussion meetings
  • Discussion of strategic implications on advice received

Meet the BaseCase team to unlock the full value of your product with engaging, data-driven communication

Imagine if payers fully understood the clinical and economic impact of your product. Many life science companies miss market access opportunities because traditional presentations (PPTs, Excel) don’t tell the full story.

BaseCase helps you clearly demonstrate improved patient outcomes, quantify economic benefits, and create interactive, data-driven narratives that engage payers—no coding required.

Visit us at ISPOR EU (Booth #1121) for a free consultation and see how BaseCase can transform your value communication strategy.

Get to know BaseCase now!

Get a guided tour of our interactive value communication apps while you are in Barcelona.


Powered by Translations.com GlobalLink Web Software